YG1699 Chinese Clinical Bridging Trial Was Launched inShanghai Xinhua Hospital
SGLT1/2 Inhibitor: Provide Full Cardiac Protection
Youngene Therapeutics Announced: Two lmportant MedicalLeaders On Board
YG1699 China Bridging Trial Has Been Carried Out
2021 ADA Update Guide: Type l Diabetes Prevention Medicine— "Teplizumab" Debut
YG1699 Has Completed Phase l Clinical Trial With 64 HealthySubjects
YG1699 Has Completed The Single Dose Climbing And 40Subjects Have Completed The ...
The First SGLT1/2 Has been Approved Clinical Trial PermissionBv NMPA in China
The Reform Plan For The Evaluation System For Clinicians WasReleased